Aptevo Therapeutics Stock Market Value
| APVO Stock | USD 6.59 0.36 5.18% |
| Symbol | Aptevo |
Will Biotechnology sector continue expanding? Could Aptevo diversify its offerings? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aptevo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Aptevo Therapeutics requires distinguishing between market price and book value, where the latter reflects Aptevo's accounting equity. The concept of intrinsic value - what Aptevo Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aptevo Therapeutics' price substantially above or below its fundamental value.
Understanding that Aptevo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aptevo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aptevo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Aptevo Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aptevo Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aptevo Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Aptevo Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Aptevo Therapeutics or generate 0.0% return on investment in Aptevo Therapeutics over 90 days. Aptevo Therapeutics is related to or competes with Kiora Pharmaceuticals, HCW Biologics, Abpro Holdings, Matinas BioPharma, In8bio, Biocardia, and Eterna Therapeutics. Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for... More
Aptevo Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aptevo Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aptevo Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.29) | |||
| Maximum Drawdown | 43.37 | |||
| Value At Risk | (10.34) | |||
| Potential Upside | 7.81 |
Aptevo Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aptevo Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aptevo Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aptevo Therapeutics historical prices to predict the future Aptevo Therapeutics' volatility.| Risk Adjusted Performance | (0.21) | |||
| Jensen Alpha | (1.95) | |||
| Total Risk Alpha | (2.43) | |||
| Treynor Ratio | (1.20) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aptevo Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aptevo Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.21) | |||
| Market Risk Adjusted Performance | (1.19) | |||
| Mean Deviation | 4.77 | |||
| Coefficient Of Variation | (366.17) | |||
| Standard Deviation | 6.72 | |||
| Variance | 45.17 | |||
| Information Ratio | (0.29) | |||
| Jensen Alpha | (1.95) | |||
| Total Risk Alpha | (2.43) | |||
| Treynor Ratio | (1.20) | |||
| Maximum Drawdown | 43.37 | |||
| Value At Risk | (10.34) | |||
| Potential Upside | 7.81 | |||
| Skewness | (1.54) | |||
| Kurtosis | 7.74 |
Aptevo Therapeutics Backtested Returns
Aptevo Therapeutics secures Sharpe Ratio (or Efficiency) of -0.28, which signifies that the company had a -0.28 % return per unit of risk over the last 3 months. Aptevo Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Aptevo Therapeutics' Mean Deviation of 4.77, risk adjusted performance of (0.21), and Standard Deviation of 6.72 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.54, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aptevo Therapeutics will likely underperform. At this point, Aptevo Therapeutics has a negative expected return of -1.92%. Please make sure to confirm Aptevo Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Aptevo Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.78 |
Good predictability
Aptevo Therapeutics has good predictability. Overlapping area represents the amount of predictability between Aptevo Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aptevo Therapeutics price movement. The serial correlation of 0.78 indicates that around 78.0% of current Aptevo Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.78 | |
| Spearman Rank Test | 0.6 | |
| Residual Average | 0.0 | |
| Price Variance | 1.23 |
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Aptevo Stock
Moving against Aptevo Stock
| 0.85 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.67 | ENGN | enGene Holdings Common | PairCorr |
| 0.66 | DSGN | Design Therapeutics | PairCorr |
| 0.62 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.55 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Aptevo Therapeutics Correlation, Aptevo Therapeutics Volatility and Aptevo Therapeutics Performance module to complement your research on Aptevo Therapeutics. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Aptevo Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.